A detailed history of Alpine Global Management, LLC transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Alpine Global Management, LLC holds 10,000 shares of SMMT stock, worth $237,600. This represents 0.07% of its overall portfolio holdings.

Number of Shares
10,000
Previous 29,149 65.69%
Holding current value
$237,600
Previous $227,000 3.52%
% of portfolio
0.07%
Previous 0.05%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$6.89 - $31.93 $131,936 - $611,427
-19,149 Reduced 65.69%
10,000 $219,000
Q2 2024

Aug 14, 2024

SELL
$2.39 - $10.92 $13,983 - $63,892
-5,851 Reduced 16.72%
29,149 $227,000
Q1 2024

May 15, 2024

BUY
$2.55 - $5.07 $12,750 - $25,350
5,000 Added 16.67%
35,000 $144,000
Q2 2023

Aug 06, 2024

SELL
$1.32 - $2.81 $6,600 - $14,050
-5,000 Reduced 14.29%
30,000 $75,000
Q2 2023

Nov 21, 2023

SELL
$1.32 - $2.81 $151,800 - $323,150
-115,000 Reduced 79.31%
30,000 $75,000
Q2 2023

Aug 14, 2023

SELL
$1.32 - $2.81 $151,800 - $323,150
-115,000 Reduced 79.31%
30,000 $75,000
Q1 2023

Nov 21, 2023

BUY
$1.38 - $5.41 $158,700 - $622,150
115,000 Added 383.33%
145,000 $253,000
Q1 2023

May 15, 2023

SELL
$1.38 - $5.41 $79,940 - $313,390
-57,928 Reduced 28.55%
145,000 $254,000
Q4 2022

Feb 14, 2023

BUY
$0.68 - $5.31 $137,991 - $1.08 Million
202,928 New
202,928 $862,000
Q2 2022

Nov 03, 2022

BUY
$0.92 - $2.38 $276,000 - $714,000
300,000 New
300,000 $300,000
Q2 2022

Aug 15, 2022

SELL
$0.92 - $2.38 $0 - $0
0 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$2.0 - $3.45 $0 - $0
0 New
0 $380,000
Q1 2022

May 13, 2022

BUY
$2.0 - $3.45 $0 - $0
0 New
0 $380,000

Others Institutions Holding SMMT

About Summit Therapeutics Inc.


  • Ticker SMMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 201,215,008
  • Market Cap $4.78B
  • Description
  • Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...
More about SMMT
Track This Portfolio

Track Alpine Global Management, LLC Portfolio

Follow Alpine Global Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpine Global Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpine Global Management, LLC with notifications on news.